|
市場調査レポート
商品コード
1462450
湿疹治療薬の世界市場 2024-2028Global Eczema Therapeutics Market 2024-2028 |
||||||
カスタマイズ可能
|
湿疹治療薬の世界市場 2024-2028 |
出版日: 2024年04月01日
発行: TechNavio
ページ情報: 英文 172 Pages
納期: 即納可能
![]() |
湿疹治療薬市場は2023-2028年に58億1,000万米ドル、予測期間中のCAGRは10.28%で成長すると予測されます。
当レポートでは、湿疹治療薬市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。
現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、アトピー性皮膚炎の有病率の高さ、湿疹治療のための製品上市の増加、エンドユーザーにおける市販(OTC)湿疹治療薬の需要増加が牽引しています。
市場範囲 | |
---|---|
基準年 | 2024 |
終了年 | 2028 |
予測期間 | 2024-2028 |
成長モメンタム | 加速 |
前年比2024年 | 9.55% |
CAGR | 10.28% |
増分額 | 58億1,000万米ドル |
本調査では、湿疹治療薬における遠隔医療プラットフォームの採用が増加していることが、今後数年間の湿疹治療薬市場成長を牽引する主要因の1つであると分析しています。また、湿疹治療への生物学的療法の採用拡大や、湿疹治療薬の需要を急増させるヘルスケア支出の増加も、市場の大きな需要につながります。
Exhibits:
The eczema therapeutics market is forecasted to grow by USD 5.81 bn during 2023-2028, accelerating at a CAGR of 10.28% during the forecast period. The report on the eczema therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of atopic dermatitis, increasing product launches for treating eczema, and increase in demand for over-the-counter (OTC) eczema drugs among end-users.
Technavio's eczema therapeutics market is segmented as below:
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 9.55% |
CAGR | 10.28% |
Incremental Value | $5.81bn |
By Application
By Distribution Channel
By Geographical Landscape
This study identifies the rising adoption of telemedicine platforms in eczema therapeutics as one of the prime reasons driving the eczema therapeutics market growth during the next few years. Also, growing adoption of biologic therapies for eczema treatment and increasing healthcare expenditure surging demand for eczema therapeutics will lead to sizable demand in the market.
The report on the eczema therapeutics market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eczema therapeutics market vendors that include AbbVie Inc., Alliance Pharma PLC, Amneal Pharmaceuticals Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd., Eli Lilly and Co., Incyte Corp., LEO Pharma AS, Lupin Ltd., Mayo Clinic, Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the eczema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.